Zobrazeno 1 - 10
of 123
pro vyhledávání: '"Michael D. Feher"'
Autor:
Anna K. Forbes, William Hinton, Michael D. Feher, William Elson, Mark Joy, José M. Ordóñez-Mena, Xuejuan Fan, Nicholas I. Cole, Debasish Banerjee, Rebecca J. Suckling, Simon de Lusignan, Pauline A. Swift
Publikováno v:
EClinicalMedicine, Vol 68, Iss , Pp 102426- (2024)
Summary: Background: The cardiovascular and kidney benefits of sodium-glucose co-transporter-2 (SGLT2) inhibitors in people with chronic kidney disease (CKD) are well established. The implementation of updated SGLT2 inhibitor guidelines and prescribi
Externí odkaz:
https://doaj.org/article/e0baed73b1194984b55afe9edc737587
Publikováno v:
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-8 (2021)
Abstract Background Sodium-glucose co-transporter-2 inhibitors (SGLT-2is) are licenced for initiation for glucose lowering in people with type 2 diabetes (T2DM) with an estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m2). However, recen
Externí odkaz:
https://doaj.org/article/bcd9962591c74bf6a7dd659993f8b555
Metabolism of phytanic acid and 3-methyl-adipic acid excretion in patients with adult Refsum disease
Autor:
Anthony S. Wierzbicki, Phillip D. Mayne, Matthew D. Lloyd, David Burston, Guam Mei, Margaret C. Sidey, Michael D. Feher, F. Brian Gibberd
Publikováno v:
Journal of Lipid Research, Vol 44, Iss 8, Pp 1481-1488 (2003)
Adult Refsum disease (ARD) is associated with defective α-oxidation of phytanic acid (PA). ω-Oxidation of PA to 3-methyl-adipic acid (3-MAA) occurs although its clinical significance is unclear. In a 40 day study of a new ARD patient, where the pla
Externí odkaz:
https://doaj.org/article/a7f9340b180b4258bfe9d4d09a71c4e5
Autor:
William Hinton, Abdus Samad Ansari, Martin B. Whyte, Andrew P. McGovern, Michael D. Feher, Neil Munro, Simon de Lusignan
Publikováno v:
Diabetes, Obesity and Metabolism. 25:501-515
To determine the absolute risk reduction (ARR) of heart failure events in people treated with sodium-glucose co-transporter-2 (SGLT2) inhibitors.We searched PubMed, EMBASE, CINAHL and ISI Web of Science for observational studies published to 9 May 20
Autor:
Anna K. Forbes, Rebecca J. Suckling, William Hinton, Michael D. Feher, Debasish Banerjee, Nicholas I. Cole, Simon de Lusignan, Pauline A. Swift
Publikováno v:
Diabetes, Obesity and Metabolism.
Autor:
null Anna K. Forbes, null Rebecca J. Suckling, null William Hinton, null Michael D. Feher, null Debasish Banerjee, null Nicholas I. Cole, null Simon de Lusignan, null Pauline A. Swift
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba733a04ab4f67739883233c0f0ef6b1
https://doi.org/10.1111/dom.15111/v2/response1
https://doi.org/10.1111/dom.15111/v2/response1
Autor:
null William Hinton, null Abdus Samad Ansari, null Martin B. Whyte, null Andrew P. McGovern, null Michael D. Feher, null Neil Munro, null Simon de Lusignan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0cf78020a6c1e0aeb2959b1d88144d3
https://doi.org/10.1111/dom.14893/v2/response1
https://doi.org/10.1111/dom.14893/v2/response1
Publikováno v:
Diabetic Medicine
Aim To identify people in English primary care with equivalent cardiovascular risk to participants in the sodium–glucose co‐transporter‐2 inhibitor (SGLT‐2i) cardiovascular outcome trials (CVOTs). A secondary objective was to report the usage
Autor:
Neil Munro, William Hinton, Michael D. Feher, Mark Joy, Simon de Lusignan, John H. H. Williams
Publikováno v:
Atherosclerosis
Background and aims Statin therapy is administered to patients with high cardiovascular risk. These patients are also at risk for severe course of coronavirus disease 2019 (COVID-19). Statins exhibit not only cardioprotective but also immunomodulator
Publikováno v:
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-8 (2021)
Cardiovascular Diabetology
Cardiovascular Diabetology
Background Sodium-glucose co-transporter-2 inhibitors (SGLT-2is) are licenced for initiation for glucose lowering in people with type 2 diabetes (T2DM) with an estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m2). However, recent trial d